42C Stock Overview
A specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
iX Biopharma Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | S$0.022 |
52 Week High | S$0.057 |
52 Week Low | S$0.022 |
Beta | 0.76 |
1 Month Change | -8.33% |
3 Month Change | -12.00% |
1 Year Change | -47.62% |
3 Year Change | -89.77% |
5 Year Change | -88.94% |
Change since IPO | -96.07% |
Recent News & Updates
Recent updates
Shareholder Returns
42C | SG Pharmaceuticals | SG Market | |
---|---|---|---|
7D | 0% | 1.0% | 0.6% |
1Y | -47.6% | 6.5% | 16.1% |
Return vs Industry: 42C underperformed the SG Pharmaceuticals industry which returned 6.5% over the past year.
Return vs Market: 42C underperformed the SG Market which returned 16.1% over the past year.
Price Volatility
42C volatility | |
---|---|
42C Average Weekly Movement | 9.7% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 4.2% |
10% most volatile stocks in SG Market | 12.3% |
10% least volatile stocks in SG Market | 1.9% |
Stable Share Price: 42C's share price has been volatile over the past 3 months compared to the SG market.
Volatility Over Time: 42C's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of SG stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 42 | Eddy Lee | www.ixbiopharma.com |
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia.
iX Biopharma Ltd. Fundamentals Summary
42C fundamental statistics | |
---|---|
Market cap | S$20.32m |
Earnings (TTM) | -S$10.79m |
Revenue (TTM) | S$5.96m |
3.3x
P/S Ratio-1.8x
P/E RatioIs 42C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
42C income statement (TTM) | |
---|---|
Revenue | S$5.96m |
Cost of Revenue | S$4.91m |
Gross Profit | S$1.05m |
Other Expenses | S$11.84m |
Earnings | -S$10.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.012 |
Gross Margin | 17.59% |
Net Profit Margin | -181.14% |
Debt/Equity Ratio | 107.6% |
How did 42C perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/07 10:46 |
End of Day Share Price | 2025/02/07 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
iX Biopharma Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Lee Keng Ling | DBS Bank Ltd |
Paul Chew | Phillip Securities Pte Ltd |
Wee Kuang Tay | Phillip Securities Pte Ltd |